Every material Form 8-K NEPHROS INC has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nephros reported third quarter 2026 net revenue of $5.6 million, up 18% from $4.8 million a year earlier, and net income of $0.5 million, up from $0.3 million. For the first nine months, net revenue rose 20% to $16.9 million and net income reached $1.8 million, but gross margin narrowed, and the company cited a $0.6 million IEEPA tariff refund that helped the nine-month result.
Q3 2026 net revenue $5.6 million vs. $4.8 million in Q3 2025, up 18%; gross margin 58% vs. 61%
Q3 2026 net income $0.5 million ($0.05 per diluted share) vs. $0.3 million; Adjusted EBITDA $0.6 million vs. $0.4 million
Nine-month net income $1.8 million vs. $1.1 million; cash and cash equivalents about $4.5 million as of September 30, 2026, debt free
Nephros said its 2026 Annual Meeting of Stockholders will be held virtually on November 25, 2026, at 11:00 a.m. Eastern Time, with a record date of September 30, 2026. Because the meeting date moved more than 30 days from the anniversary of its June 16, 2025 meeting, the company set new deadlines for stockholder proposals and director nominations, which shareholders who want to submit them should note.
Annual meeting: November 25, 2026, at 11:00 a.m. Eastern Time, held virtually by live webcast
Record date for stockholders entitled to notice of and to vote: close of business September 30, 2026
Deadline for Rule 14a-8 stockholder proposals and Rule 14a-19 nominee notices: October 23, 2026
Prior 2025 deadlines no longer apply; the 2025 annual meeting was held June 16, 2025
Nephros reported second quarter 2026 net revenue of $6 million, up 36% from $4.4 million a year earlier, and net income of $1.2 million versus $0.2 million. Net income includes a one-time tariff refund of approximately $0.6 million, and the company stated it has not yet received the refund, booking it as a receivable. Revenue growth and higher profit both improved, though gross margin rose largely because of the one-time refund.
Q2 2026 net revenue was a record $6 million, up 36% from $4.4 million; core programmatic revenue grew 27%
Q2 2026 net income was $1.2 million, or $0.11 per diluted share, versus $0.2 million, or $0.02, a year earlier
Net income includes a one-time IEEPA tariff refund of approximately $0.6 million; cash and equivalents were $4.7 million at June 30, 2026, and the company reports no debt
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NEPHROS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →